Bictegravir/emtricitabine/tenofovir alafenamide for HIV: a meta-analysis of efficacy across treatment-naïve and experienced populations and comparative effectiveness versus dolutegravir/lamivudine
Frontiers in Pharmacology · 30.10.2026 · 17
DOI: 10.3389/fphar.2026.1935865 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Pharmacology, online erschienen am 30.10.2026. Verfasst von Mingxia Cheng und 8 weiteren Autor:innen. Beteiligte Einrichtung: The First Clinical School of Gansu University of Chinese Medicine, Lanzhou, China. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Gansu Province.
Abstract (Originalsprache)
Objectives
Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) is a preferred single-tablet regimen for HIV treatment, but head-to-head meta-analytic comparisons between treatment-experienced (TE) and treatment-naïve (TN) individuals are lacking. Additionally, the comparative effectiveness of BIC/FTC/TAF versus dolutegravir/lamivudine (DTG/3TC) remains to be systematically synthesized. We aimed to systematically compare the efficacy of BIC/FTC/TAF between TE and TN people with HIV, and evaluate the comparative effectiveness of BIC/FTC/TAF versus DTG/3TC.
Methods
We searched PubMed, Cochrane Library, Web of Science, and Embase up to September 2026. Observational studies and randomized controlled trials (RCTs) reporting virologic suppression or treatment discontinuation rates in both TE and TN populations receiving BIC/FTC/TAF, or BIC/FTC/TAF versus DTG/3TC were included. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. Single-group proportion meta-analyses used a random-effects model, whereas comparative meta-analyses used the prespecified fixed-effect model.
Results
Thirty-one studies were included. For TE participants, the pooled virologic suppression rate was 95% (95% CI: 92%–97%) at 12 months, and for TN participants, the rate was 90% (95% CI: 85%–94%). In design-stratified comparative analyses between BIC/FTC/TAF and DTG/3TC, no statistically significant difference was detected in RCT (OR = 1.46, 95% CI: 0.80–2.66) or cohort studies (OR = 0.98, 95% CI: 0.70–1.39) among TN populations, nor in TE populations (RCT: OR = 1.04, 95% CI: 0.34–3.16; cohort: OR = 0.92, 95% CI: 0.42–2.02). No statistically significant differences were detected for treatment discontinuation (all-cause: OR = 1.02, 95% CI: 0.70–1.49; adverse events: OR = 1.11, 95% CI: 0.55–2.22).
Conclusion
BIC/FTC/TAF achieves high virologic suppression rates and low discontinuation rates in both TE and TN populations, supporting its use as a first-line and switch option. BIC/FTC/TAF and DTG/3TC showed no statistically significant differences in virologic suppression or treatment discontinuation, suggesting both are viable guideline-preferred options. The choice between them should be individualized based on patient characteristics, including prior treatment history, adherence potential, comorbidity profile, and metabolic risk considerations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The First Clinical School of Gansu University of Chinese Medicine, Lanzhou, China.
- Institute of Evidence-Based Medicine, Gansu Provincial Hospital, Lanzhou, China.
- Department of HIV/AIDS and other Sexually Transmitted Diseases Control and Prevention, Heze Center for Disease Control and Prevention (Heze Health Supervision Institute), Heze, Shandong, China.
- Department of Scientific Research, Gansu Provincial Hospital, Lanzhou, China.
- The First Clinical Medical College, Lanzhou University, Lanzhou, China.
- Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China.
Förderung
- Natural Science Foundation of Gansu Province
Zitieren
APA
Cheng, M., Wang, A., Zhu, Q., Duan, H., Guo, K., Li, L., Ma, S., He, J., & Yang, K. (2026). Bictegravir/emtricitabine/tenofovir alafenamide for HIV: a meta-analysis of efficacy across treatment-naïve and experienced populations and comparative effectiveness versus dolutegravir/lamivudine. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1935865
Vancouver
Cheng M, Wang A, Zhu Q, Duan H, Guo K, Li L, et al. Bictegravir/emtricitabine/tenofovir alafenamide for HIV: a meta-analysis of efficacy across treatment-naïve and experienced populations and comparative effectiveness versus dolutegravir/lamivudine. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1935865
BibTeX
@article{Cheng2026,
author = {Cheng, Mingxia and Wang, Aiwen and Zhu, Qingshuang and Duan, Hua and Guo, Kangle and Li, Li and Ma, Shixun and He, Jin and Yang, Kehu},
title = {Bictegravir/emtricitabine/tenofovir alafenamide for HIV: a meta-analysis of efficacy across treatment-naïve and experienced populations and comparative effectiveness versus dolutegravir/lamivudine},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1935865}
}
EUVIMED